TEAD1 and cardiac hypertrophy: Overall, AAV‐TEAD1‐WT effectively inhibited TAC surgery‐induced cardiac hypertrophy, heart dysfunction, and heart remodeling whereas AAV‐TEAD1‐K177R aggravated pressure overload‐induced cardiac hypertrophy.